21 completed, 2 not yet recruiting, 1 terminated. 8 Phase 2, 7 Phase 3, 6 Phase 1, 3 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Completed 8 |
| Phase 3 | 7 | Completed 6, Terminated 1 |
| Phase 1 | 6 | Completed 6 |
| Phase 4 | 3 | Not yet recruiting 2, Completed 1 |
Follow Tris Pharma, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| EEG Biomarkers for ADHD Stimulant Treatment methylphenidate HCl, Mixed amphetamine salts extended release - ADHD | Phase 4 | Not yet recruiting | Boston Children's Hospital | 220 | 2026-09-15 | 2026-06-16 |
| A Study to Assess the Effectiveness and Safety of Clonidine Extended-Release OnydaTM XR in Children With ADHD and ODD Clonidine extended release oral suspension, Placebo - Attention-deficit/Hyperactivity Disorder, Oppositional Defiant Disorder in Children | Phase 4 | Not yet recruiting | Las Vegas Medical Research, LLC DBA Vector Clinical Trials | 162 | 2025-07-01 | 2025-07-01 |
| A Study of Cebranopadol for the Treatment of Acute Pain After Abdominoplasty Cebranopadol 400 ug, Cebranopadol 200 ug, Placebo - Acute Pain | Phase 3 | Completed | Tris Pharma, Inc. | 279 | 2024-09-03 | 2026-01-22 |
| A Study of Cebranopadol for the Treatment of Acute Pain After Bunionectomy Cebranopadol, Oxycodone IR, Placebo Only - Acute Pain | Phase 3 | Completed | Tris Pharma, Inc. | 240 | 2024-07-18 | 2026-01-26 |
| A Study to Assess the Abuse Potential of Intranasal Cebranopadol Cebranopadol- 600 ug, Cebranopadol- 800ug, Cebranopadol- 1000ug - Abuse, Drug | Phase 1 | Completed | Tris Pharma, Inc. | 48 | 2024-06-28 | 2025-12-18 |
| Cebranopadol Effects on Ventilatory Drive, Central Nervous System (CNS) and Pain. Cebranopadol 600 µg, Cebranopadol 800 µg, Cebranopadol 1000 µg - Pain | Phase 1 | Completed | Tris Pharma, Inc. | 30 | 2022-07-29 | 2024-05-09 |
| Assessment of Abuse Potential of Cebranopadol in Humans Oxycodone 40 mg, Tramadol 600 mg, Placebo - Human Abuse Potential | Phase 1 | Completed | Tris Pharma, Inc. | 38 | 2022-03-28 | 2022-07-27 |
| Amphetamine Extended Release Tablets and Driving Performance in Subjects With Attention Deficit/Hyperactivity Disorder (ADHD) Amphetamine Extended Release (ER) Tablet 20 mg - ADHD | Phase 2 | Completed | Tris Pharma, Inc. | 41 | 2019-10-01 | 2022-02-18 |
| Amphetamine Extended-Release Tablets in the Treatment of Adults With ADHD AMPH ER Tab 5, 10, 15 and 20 mg, AMPH ER Tab Matching Placebo 5, 10, 15 and 20 mg - ADHD | Phase 3 | Completed | Tris Pharma, Inc. | 130 | 2019-02-06 | 2023-11-02 |
| Pharmacokinetic Study of DYANAVEL XR (Amphetamine) Extended-release Oral Suspension, in Children Aged 4 to 5 Years Amphetamine Extended Release Suspension [Dyanavel] - Attention Deficit Hyperactivity Disorder | Phase 4 | Completed | Tris Pharma, Inc. | 5 | 2018-05-07 | 2019-06-25 |
| Dyanavel® XR Extended-Release Oral Suspension in the Treatment of Children With ADHD: A Laboratory School Study amphetamine extended-release oral suspension, 2.5 mg/mL, Placebo extended-release oral suspension - Attention Deficit Hyperactivity Disorder | Phase 3 | Completed | Tris Pharma, Inc. | 18 | 2017-02-11 | 2019-07-22 |
| TRI102 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD) TRI102, Placebo - Attention Deficit Disorder With Hyperactivity | Phase 3 | Completed | Tris Pharma, Inc. | 108 | 2014-03-01 | 2020-08-26 |
| CORAL XT - Open-label Extension Trial of the CORAL Trial Cebranopadol - Pain, Neoplasms | Phase 3 | Completed | Tris Pharma, Inc. | 76 | 2013-12-18 | 2021-07-15 |
| CORAL - Cebranopadol Versus Morphine Prolonged-release in Patients With Chronic Moderate to Severe Pain Related to Cancer Cebranopadol, Morphine Prolonged Release - Pain, Neoplasms | Phase 3 | Terminated | Tris Pharma, Inc. | 200 | 2013-10-29 | 2021-07-15 |
| Cebranopadol Efficacy and Safety in Diabetic Patients Suffering From Chronic Pain Caused by Damage to the Nerves Cebranopadol 100 µg, Cebranopadol 300 µg, Cebranopadol 600 µg - Chronic Pain, Diabetic Neuropathies | Phase 2 | Completed | Tris Pharma, Inc. | 699 | 2013-09-27 | 2021-07-15 |
| Evaluation of the Effects of Multiple Doses of Cebranopadol on the Electrical Activity of the Heart in Healthy Subjects 100 μg cebranopadol, 200 μg cebranopadol, 400 μg cebranopadol - Prolonged QTc Interval, Pharmacokinetic | Phase 1 | Completed | Tris Pharma, Inc. | 171 | 2013-07-10 | 2021-07-15 |
| A Clinical Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of Cebranopadol Cebranopadol 200 μg tablet - Pharmacokinetic | Phase 1 | Completed | Tris Pharma, Inc. | 34 | 2013-06-20 | 2021-07-15 |
| A Trial to Evaluate the Abuse Potential of 3 Doses of GRT6005 in Adult Non-dependent Recreational Opioid Users Cebranopadol 100 micrograms, Cebranopadol 400 micrograms, Hydromorphone hydrochloride 4 milligrams - Abuse, Drug | Phase 1 | Completed | Tris Pharma, Inc. | 226 | 2013-04-15 | 2021-07-15 |
| Safety and Efficacy Study of GRT6005 in Patients With Osteoarthritis (OA) Knee Pain Cebranopadol (GRT6005) Low-Dose Range, Cebranopadol (GRT6005) High-Dose Range, Placebo - Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee | Phase 2 | Completed | Tris Pharma, Inc. | 619 | 2012-12-04 | 2021-07-15 |
| Efficacy and Safety of GRT6005 in Patients With Chronic Low Back Pain. Matching Placebo, Low Dose GRT6005, Medium Dose GRT6005 - Low Back Pain | Phase 2 | Completed | Tris Pharma, Inc. | 1089 | 2012-11-01 | 2021-07-15 |
Showing 20 of 24. Sign in to see all of them.
Attention Deficit Disorder with Hyperactivity (7) · Pain (7) · Chronic Pain (4) · Diabetic Neuropathies (3) · Acute Pain (2) · Agnosia (2) · Cancer Pain (2) · Diabetes Mellitus (2) · Neoplasms (2) · Substance-Related Disorders (2) · Arthritis (1) · Bronchiolitis Obliterans Syndrome (1) · Hypercapnia (1) · Low Back Pain (1) · Neuralgia (1)
6'-fluoro-4',9'-dihydro-N,N-dimethyl-4-phenylspiro(cyclohexane-1,1'(3'H)-pyrano(3,4-b)indol)-4-amine (11) · Oxycodone (3) · Amphetamine (2) · Tablets (2) · Hydromorphone (1) · Methylphenidate (1) · Morphine (1) · Moxifloxacin (1) · Pregabalin (1) · TRI102 protein, Gibberella zeae (1) · Tapentadol (1) · Tramadol (1)
United States (15) · Germany (6) · Austria (5) · Denmark (4) · Poland (4) · Spain (4) · Belgium (3) · Bulgaria (3) · Hungary (3) · Netherlands (3) · Romania (3) · United Kingdom (3) · Serbia (2) · Slovakia (2) · Canada (1)
Albert Dahan, MD, PhD (1) · Andrew J. Cutler, MD (1) · Angela Eakin, MD (1) · Ann Childress, MD (1) · Antonio Pardo, MD (1) · Geert Jan Groeneveld, MD, PhD (1) · Harold S. Minkowitz, MD (1) · Jacek Olas, MD (1) · John Bothmer, Dr. (1) · Joseph Biederman, MD (1) · Sally Berry, MD, PhD (1) · Sharon Wigal, PhD (1)
PMID 30365202, PMID 30575407, PMID 31152783, PMID 35857716, PMID 36730749